FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

25 letters match. Newest first.

  1. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  2. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  3. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  4. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  5. Maria A. Carballosa, M.D.

    FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.

    Medium
  6. Sprout Health Partners LLC dba Sprout Health

    FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.

    Low
  7. Mark J. Savant, M.D

    FDA warns clinical investigator Mark J. Savant, M.D., over protocol dosing and eligibility failures and missing informed consent in a drug trial.

    High risk
  8. Peter Michael, M.D.

    FDA warns clinical investigator Peter Michael, M.D. that pediatric trial subjects received twice the protocol's maximum drug dose.

    High risk
  9. Richard W. Foltin, Ph.D.

    FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.

    High risk
  10. Armstrong County Memorial Hospital

    FDA warns Armstrong County Memorial Hospital review board over missing procedures and inadequate meeting minutes for drug research.

    Medium
  11. Louisiana State University Health Science Center IRB

    FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.

    Medium
  12. Konrad Rejdak, M.D., Ph.D.

    FDA warns Dr. Konrad Rejdak over clinical trial data integrity failures in a CIDP immune globulin study.

    Medium
  13. New York State Psychiatric Institute IRB

    FDA warned New York State Psychiatric Institute's review board it failed to report serious research problems and reviewed drug studies without required nonscientific member.

    High risk
  14. Anish S. Shah, M.D./Siyan Clinical Research

    FDA warned clinical investigator Dr. Anish Shah that he broke blinding rules in a depression drug study, calling the site's data into question.

    Medium
  15. Melanie M. Hoppers, M.D./Physicians Quality Care

    FDA warns Dr. Melanie Hoppers over enrolling ineligible patients in a baloxavir marboxil influenza trial.

    High risk
  16. Luis Javier Pena-Hernandez, M.D., FCCP

    FDA warns Dr. Pena-Hernandez over ineligible subject enrollment and lapsed IRB approval for investigational drugs.

    High risk
  17. Angela M. Stupi, M.D.

    Clinical investigator Angela M. Stupi, M.D. enrolled ineligible subjects and injected study drug at wrong body sites in two trials.

    High risk
  18. Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

    FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.

    High risk
  19. Adarsh Daswani, M.D.

    Clinical investigator Adarsh Daswani, M.D. failed to follow protocol dosing and oversight for an investigational drug study.

    High risk
  20. "David M. Lubeck, M.D./Arbor Centers for EyeCare

    FDA warned Dr. David Lubeck for running a combination-drug study without an IND and enrolling five subjects.

    High risk
  21. Smitha C. Reddy, M.D./ACRC Studies, LLC

    FDA warns Dr. Smitha Reddy over clinical trial protocol violations, including wrong drug given and broken blinding.

    High risk
  22. "Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases

    FDA warns clinical investigator Daniel C. Tarquinio over enrolling ineligible subjects in investigational drug trials.

    High risk
  23. Lauren R. Klein, MD, M.S.

    FDA cited Dr. Lauren R. Klein for running two emergency department drug studies without required investigational new drug applications.

    High risk
  24. Jon B. Cole, MD

    FDA warns Dr. Jon B. Cole he ran two pre-hospital drug studies without required INDs, adding risks for pregnant women, children, and intoxicated patients.

    High risk
  25. Evelyn Lopez-Brignoni, M.D.

    FDA warns Dr. Evelyn Lopez-Brignoni over inadequate dosing in pediatric investigational drug trials.

    High risk